ClinicalTrials.gg

Program

BAY 3389934

A development code. Also written as “BAY3389934”.

Its studies are mostly in Sepsis, led by Bayer.

Furthest: phase 1, since Feb 28, 20253 company-led studies, 2 open or runningNext primary completion: Dec 25, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bayer32 open or runningphase 1since Feb 28, 2025Feb 28, 2025Dec 25, 2026phase 1 · NCT06854640

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 28, 2025First study: phase 1 study in SepsisFirst studyNCT06854640 · 36 planned · United States, Belgium, France and more
  2. Aug 29, 2025Phase 1 study in SepsisNCT07176728 · 16 enrolled · Japan
  3. Jun 8, 2026Phase 1 study in Drug-drug InteractionNCT07652723 · 16 planned · United States

Ahead

  1. Dec 25, 2026Primary completion: phase 1 study in SepsisNCT06854640
  2. Mar 10, 2027Primary completion: phase 1 study in Drug-drug InteractionNCT07652723

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07652723Drug-drug Interaction · United States1RecruitingMar 10, 202716
NCT07176728Sepsis · Japan1CompletedMay 17, 202616
NCT06854640Sepsis · United States, Belgium, France and more1RecruitingDec 25, 202636

How it is read

Names in the registry

  • “BAY3389934”, 2 entries
  • “BAY 3389934”, 1 entry

Codes read as this program: BAY3389934.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.